Tuberculosis and beta-lactam antibiotics

Gun M. A., BOZDOĞAN B., ÇOBAN A. Y.

FUTURE MICROBIOLOGY, vol.15, no.10, pp.937-944, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 15 Issue: 10
  • Publication Date: 2020
  • Doi Number: 10.2217/fmb-2019-0318
  • Journal Name: FUTURE MICROBIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.937-944
  • Keywords: beta-lactams, MDR, tuberculosis, XDR, DRUG-RESISTANT TUBERCULOSIS, MEROPENEM-CLAVULANIC ACID, MYCOBACTERIUM-TUBERCULOSIS, IN-VITRO, ANTITUBERCULOSIS DRUGS, TREAT MULTIDRUG, COMBINATION, CARBAPENEMS, EFFICACY, SUSCEPTIBILITY
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Tuberculosis (TB) is one of the oldest health problems in the world and it remains unresolved. Multidrug-resistant-TB and extensively resistant-TB are a serious problem for control programs. The evaluation of available antibiotics has gained importance in recent years for the treatment of resistant TB. Beta-lactam antibiotics inhibit cell wall biosynthesis in the bacteria; the presence of beta-lactamase enzyme in TB bacilli raises the question of whether this group of antibiotics can be used in treatment. As a result, it has been reported that the combination of beta-lactam antibiotics with beta-lactamase is effective againstMycobacterium tuberculosisbothin vitroandin vivo. The aim of this article is to review and discuss up-to-date knowledge and future perspective on beta-lactam antibiotics and TB.